Ozempic overview
Brand name for semaglutide, FDA-approved for type 2 diabetes mellitus. Same active ingredient as Wegovy and Rybelsus.
Ozempic at a glance
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
The Ozempic injection label (effective July 30, 2026) covers blood-sugar control in adults with type 2 diabetes, lowering cardiovascular risk in adults with type 2 diabetes and heart disease, and lowering the risk of kidney decline and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, the use tested in FLOW (NEJM 2024). It is not approved for weight management; the weight-management semaglutide is Wegovy. The CMS fact sheet on 2027 negotiated prices lists a $274 Medicare price for a 30-day supply of Ozempic from January 1, 2027, which does not change cash prices.